29
NOV
2021
Northwest Biotherapeutics Announces $15 Million Financing
Comments : Off
BETHESDA, Md., November 29, 2021 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of a $15 million financing on November 22, 2021, which brought the Company’s cash reserves above $20 million. The Company plans to use the funding to help accelerate its activities related to its brain cancer program. The... Read More